Best Practices in Action

Total Page:16

File Type:pdf, Size:1020Kb

Best Practices in Action best practices in action i ii best practices in action Guidelines for Implementing First-Class Business Incubation Programs REVISED 2ND EDITION BY Corinne Colbert, Dinah Adkins, Chuck Wolfe & Karl LaPan MCNAUGHTON & GUNN | SALINE, MICHIGAN NBIA gratefully acknowledges these sponsors who helped underwrite production of this book: iii Other Books Published by the National Business Incubation Association Speak Up! An Advocacy Toolkit for Business Incubators (PDF) Put It in Writing: Crafting Policies, Agreements, and Contracts for Your Incubator Measuring Your Business Incubator’s Economic Impact: A Toolkit (print and PDF) Incorporating Your Business Incubation Program: How Tax Status and Business Entity Affect Operations 2006 State of the Business Incubation Industry (print and PDF) Incubating in Rural Areas: Challenges and Keys to Success A Practical Guide to Business Incubator Marketing Technology Commercialization through New Company Developing a Business Incubation Program: Formation: Why U.S. Universities Are Incubating Companies Insights and Advice for Communities Incubating the Arts: Establishing a Program to Help Artists The Incubation Edge: How Incubator Quality and Regional and Arts Organizations Become Viable Businesses Capacity Affect Technology Company Performance Bricks & Mortar: Renovating or Building a Business A Comprehensive Guide to Business Incubation, Completely Incubation Facility (PDF) Revised 2nd Edition Human Resources: Finding the Right Staff for Your Incubator Incubation in Evolution: Strategies and Lessons Learned in Four Countries (print and PDF) Business Incubation Works Self-Evaluation Workbook for Business Incubators The Art & Craft of Technology Business Incubation: Best Practices, Strategies, and Tools from More Than 50 Programs Incubating Technology Businesses: A National Benchmarking Study Find these titles and others at www.nbia.org/store. A Brief History of Business Incubation in the United States Does Technology Incubation Work? A Critical Review of the Evidence (PDF) © 2010 NBIA Publications All rights reserved. Printed in the United States of America. This publication is a creative work copyrighted by the National Business Incubation Association and fully protected by all applicable copyright laws. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to Permissions, NBIA Publications, 20 East Circle Drive, #37198, Athens, Ohio 45701-3751. This work has been made possible in part by support from Claggett Wolfe Associates and Maryland TEDCO. Published by ISBN-01: 978-1-887183-69-7 McNaughton & Gunn Design by: Ullman Design 960 Woodland Drive www.ullmandesign.com Saline, MI 48176 telephone: 734.429.8757 www.bookprinters.com iviv CONTENTS ■ ■ ■ FOREWORD vii ■ ■ ■ ACKNOWLEDGMENTS ix introduction 001 .01 governance 004 .02 staffi ng 020 .03 fi nances 032 .04 facilities management 042 .05 program evaluation 054 .06 client entrance and exit 064 .07 leveraging innovation 086 .08 client services 098 .09 case studies 132 ■ ■ ■ AFTERWORD 159 ■ ■ ■ GLOSSARY 160 ■ ■ ■ BIBLIOGRAPHY 165 ■ ■ ■ PROGRAMS MENTIONED 166 ■ ■ ■ INDEX 168 V Claggett Wolfe Associates is an economic development consulting fi rm serving U.S. and international clients in support of economic growth and diversifi cation through entrepreneurship and SME development. Founded in 1996, Claggett Wolfe Associates has been engaged in all aspects of the SME development process from public policy development and program feasibility assessment to business planning and program operation. Core areas of expertise include entrepreneurship development, incubation/acceleration, technology commercialization and small business lending. The company’s strength is in its ability to assess market, economic and cultural dynamics to help its client identify opportunities, attain goals, manage expectations and maximize impacts. Since its inception, Claggett Wolfe Associates has provided services to corporations, foundations, incubators/accelerators, colleges/universities, Native American tribes and government agencies (national, state and local) for projects in Bahrain, Canada, China, Japan, Kuwait, Mexico, Saudi Arabia, Taiwan and the United States. vivi foreword Publication of this new, completely revised and expanded Best Practices in Action: Guidelines for Implementing First-Class Business Incubation Programs follows some nine years after the original. Thus, the near decade of progress in the industry should be readily evident here. Despite the fi ne models and examples presented in the earlier edition, this new volume has been enriched by the vastly increased sophistication of business incubation as it is practiced today in the United States and elsewhere. Since the nascent years of the 1980s, our understanding of how to serve entrepreneurial fi rms, commercialize technologies, create wealth, and promote entrepreneurship in our communities has increased exponentially. Therefore, we are pleased to present on these pages many activities, policies, techniques, and other examples of best practices—recognizing that there are few practices that will fi t our needs in every situation or that do not require adaptation. In some settings, even use of the term “best practice” is controversial, due to concern that it seeks to prescribe universal solutions. Given that the practice of incubation in China, France, the United States, and other nations varies based on individual cultures, resources, and needs, we are not so foolish as to suggest such iron rules. And though we still take very seriously the principles and practices approved by NBIA’s board of directors in 1996, we know they must inevitably evolve. But we believe that the managers of the programs presented here have striven for excellence. They have aspired to be more than “good enough.” Far from being prescriptive, the examples here show the creative abundance that has emerged from programs devoted, quite simply, to serving entrepreneurs in the “highest and best” manner possible. It is our hope that—inspired by this volume—readers will incubate hundreds of new ideas and propel their programs into a future that is exemplary of its own time. I am grateful to have participated in this exciting industry for twenty-eight years and have lost not an iota of excitement in anticipating your future successes. Dinah Adkins NBIA PRESIDENT EMERITA vii viii Acknowledgments This book is the result of nearly three years of work by a core group of NBIA staff and NBIA members who collaborated at every stage, from planning through editing. It has been a long, sometimes painful process, but the result is worth it. Deepest thanks go to: ■ Meredith Erlewine, NBIA’s longtime director of ■ Tracy Kitts, NBIA’s vice president and COO, whose publications, who gathered a stellar panel of incubator persistent queries about the book’s progress may managers and consultants to thoroughly revise and have been annoying at times but always kept the update an NBIA Publications classic. Meredith left project at the top of my mind even when other work NBIA in the spring of 2008, but her dogged pursuit of crowded forward. quality continues to inspire her former colleagues. ■ Rick Huard, late of the Ohio University Press, whose ■ Dinah Adkins, NBIA’s president emerita, whose sharp copyediting and proofreading whipped the fi nal unparalleled knowledge of the industry and its manuscript into shape (and prevented many a typo). practitioners was key to identifying the practices and ■ Tina Ullman and Alix Northrup of Ullman Design, who programs to highlight. Dinah also returned to her roots patiently endured multiple rounds of changes and still as a reporter to investigate and write about many of the made a gorgeous book. specifi c practices that follow. Thanks also go to David Monkman, NBIA’s new president ■ Chuck Wolfe, of Claggett Wolfe Associates, and and CEO, who came along as the BPIA whirlwind was Karl LaPan, president and CEO of the Northeast Indiana reaching its climax and remained unfazed. I look forward to Innovation Center, not only served on the book’s producing more books under David’s tenure. steering committee but also traveled around the United States and beyond to check out best practice programs The book revision would not have been possible without and write about them. Special thanks go to the support from two old friends. The Maryland Technology Foellinger Foundation, which funded LaPan’s travels. Development Corporation, which underwrote the original ■ David Terry, executive director of the West Texas A&M BPIA, again offered its fi nancial support for the book’s University Enterprise Network, provided not only his production. Likewise, Chuck Wolfe—a coauthor of the insights but also his Texas twang and sense of humor to original edition—provided funding as well as his time and long steering committee conference calls. talent. NBIA is deeply grateful to both of these longtime supporters for their continued generosity and faith. ■ Jasper Welch, director of the San Juan College Enterprise Center, and Joel Wiggins, president and Finally, thanks go to the dozens of NBIA members who CEO of the Enterprise Center of Johnson County, submitted proposals for inclusion in the book; who agreed to read early drafts of the chapters and provided both repeated rounds of interviews; and who answered my calls their points of view and a number
Recommended publications
  • PROTALIX BIOTHERAPEUTICS, INC. (Exact Name of Registrant As Specified in Its Charter)
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K FOR ANNUAL AND TRANSITION REPORTS PURSUANT TO SECTIONS 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to 001-33357 (Commission file number) PROTALIX BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Florida 65-0643773 State or other jurisdiction (I.R.S. Employer of incorporation or organization Identification No.) 2 Snunit Street Science Park POB 455 Carmiel, Israel 20100 (Address of principal executive offices) (Zip Code) 972-4-988-9488 Registrant’s telephone number, including area code Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common stock, par value $0.001 per share NYSE MKT Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ¨ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ¨ No x Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Opko Health: the Placebo Effect
    Opko Health: The Placebo Effect Lakewood Capital Management December 2013 /placebo effect/ (plah-se’bo ĕ-fekt’), noun [L.]: 1. the beneficial effect that occurs following a treatment administered to a group that arises simply from that group’s faith or preconceptions that the treatment will work. 2. an ineffectual treatment intended to deceive the recipient. Table of Contents A.) Executive Summary ................................................................................................... 1 B.) A Dizzying History Of Deals and Disappointment .................................................. 8 C.) Poor Financial Results… Yet A Soaring Market Capitalization ............................. 15 D.) Latin American Drug Distribution ........................................................................... 17 E.) Exploratory Alzheimer’s Diagnostic ...................................................................... 18 F.) Claros Diagnostics ................................................................................................... 19 G.) 4Kscore™ Exploratory Prostate Cancer Screening Test ......................................... 22 H.) Rayaldy .................................................................................................................... 26 I.) Prolor Biotech .......................................................................................................... 30 J.) A Web Of Stock Promotion ..................................................................................... 33 K.) Insider Share Purchases
    [Show full text]
  • Signature Redacted
    VC Funding Elements in US-Israel Case and Application to China-Korea By Anna Lee B.S. Business Administration, Finance and Corporate Management California State University, East Bay, 2012 SUBMITTED TO THE MIT SLOAN SCHOOL OF MANAGEMENT IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE IN MANAGEMENT STUDIES AT THE MASSACHUSETTS INSTITUTE OF TECHNOLOGY JUNE 2017 @2017 Anna Lee. All rights reserved. The author hereby grants to MIT permission to reproduce and to distribute publicly paper and electronic copies of this thesis document in whole or in part in any medium now known or hereafter created. Signature redacted Signature of Author: V MIT Sloan S chool of Management May 12, 2017 Signature redacted Certified by: Jake Cohen Seniot Associate Dean for Undergraduate and Master's Programs Thesis Supervisor Signature redacted Accepted by: MASSA H IsENSTITUTE Rodrigo Verdi OFTEHNLGY Associate Professor of Accounting JUN 2 0 2017 Program Director, M.S. in Management Studies Program LIBRARIES ARCHIVES 77 Massachusetts Avenue Cambridge, MA 02139 MITLibraries http://Iibraries.mit.edu/ask DISCLAIMER NOTICE Due to the condition of the original material, there are unavoidable flaws in this reproduction. We have made every effort possible to provide you with the best copy available. Thank you. The images contained in this document are of the best quality available. Th c ppo n K> 2 VC Funding Elements in US-Israel Case and Application to China-Korea By Anna Lee Submitted to MIT Sloan School of Management on May 12, 2017 in Partial Fulfillment of the requirements for the Degree of Master of Science in Management Studies.
    [Show full text]
  • Life Sciences in Israel
    Inspiration Invention Innovation Life Sciences in Israel www.investinisrael.gov.il Life Sciences in Israel Table of Contents Israel: A Powerhouse of Opportunities Israel: A Powerhouse of Opportunities .................................................3 Over the last decade, Israel has introduced a wealth of groundbreaking Why Israel’s Life Sciences? and valuable innovations in life sciences. Israel’s life sciences sector is Israel’s Life Science Sectors ..................................................................4 supported by a strong foundation of academic excellence, including some Over 1,000 life sciences Medical Devices of the world’s leading research institutes, renowned R&D facilities and companies - biopharma and Biopharmaceuticals cutting-edge medical centers. Bolstered by a highly skilled workforce, a medical devices Healthcare IT flourishing high-tech environment, and an entrepreneurial spirit, Israeli companies have been joined by leading multinationals in making Israel a Over 1/3 of LS Start-Ups Israel’s Biomedical Engineering: recognized force in the industry worldwide. Global giants, including Johnson already generate revenue. Spotlight on Stem Cell Research .........................................................11 & Johnson, Perrigo, GE Healthcare, Phillips Medical, Abbott Laboratories, Source of numerous Merck Serono and Sanofi together with local companies such as Teva, itself blockbuster drugs such Israel’s Life Sciences Competitive Edge ..............................................15 a multinational company,
    [Show full text]